Related coverage linked through entity extraction aliases.
Apr 25, 2026
A U.K. focus-group study found support for sharing health data for AI is conditional on public benefit, safeguards and meaningful consent. The findings come as Europe tightens control over biomedical datasets under data-sovereignty policies.
Apr 24, 2026
The real-world data market is projected to grow from $2.34 billion in 2026 to $4.21 billion by 2030. Growth is driven by EHR adoption, regulatory acceptance of real-world evidence, and AI-driven analytics.
Apr 10, 2026
Durvalumab has been approved for rollout on the NHS for muscle-invasive bladder cancer. In a trial of more than 1,000 patients, it cut the risk of progression by 32% versus standard care.
Apr 07, 2026
Boots has launched an in-store weight loss service across 17 UK locations, offering face-to-face consultations for weight-loss injections like Wegovy and Mounjaro. The service includes a 10-week free weight loss programme and 12-month aftercare, with prices starting at £99.97 for Wegovy. This marks the first high street pharmacy to provide such in-person weight loss treatment consultations.
Mar 25, 2026
NICE has upheld appeals to review its guidance on Alzheimer's drugs lecanemab and donanemab, sending the decision back to committee. The manufacturers argued NICE failed to account for the treatments' wider impact on unpaid carers. This comes amid broader challenges in neurodegenerative disease research following recent high-profile clinical trial failures.
Mar 21, 2026
Ten-year survival data show salvage focal therapy using heat or cold ablation is as effective as radical prostatectomy for treating localized prostate cancer recurrence after radiotherapy, with significantly fewer complications and better quality of life.
Mar 19, 2026
Analysis shows around a third of 54 drugs on TrumpRx.gov are cheaper in the UK, while the platform offers significant savings primarily for obesity and fertility drugs not typically covered by insurance.
Mar 17, 2026
New NICE guidance recommends offering SGLT-2 inhibitors earlier in type 2 diabetes treatment, potentially preventing 17,000 deaths over three years while saving the NHS £560 million through generic medicines.
Mar 09, 2026
Grail's NHS-Galleri trial of 142,000 participants failed to achieve statistically significant reduction in late-stage cancer diagnoses, though secondary endpoints showed four-fold improvement in overall cancer detection rate. Stock fell 48% following the announcement.
Feb 26, 2026
Approved gene-editing therapies for sickle cell disease priced at $2.2 million remain out of reach in Africa, where 80% of the world's cases occur, as Uganda launches mandatory newborn screening.
Feb 20, 2026
Grail's multi-cancer blood test failed to significantly boost early detection or reduce late-stage diagnoses in a 142,000-person UK trial, raising doubts about regulatory approval and commercial prospects.
Feb 18, 2026
Researchers develop machine-learned biomarker predicting liver cancer risk with 93% accuracy, while AI-driven drug repurposing offers faster, cost-effective alternatives to address cancer survivorship gaps.
Feb 17, 2026
Scientists are developing blood tests that can detect cancer years before symptoms appear, including CRISPR-powered sensors and multi-cancer early detection tests that identify molecular warning signs in the bloodstream.
Feb 13, 2026
PTC Therapeutics withdrew its resubmitted new drug application for Translarna in Duchenne muscular dystrophy after the FDA indicated the data was unlikely to meet the threshold for substantial evidence of effectiveness, marking the third unsuccessful US approval attempt.
